562 related articles for article (PubMed ID: 18454043)
1. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
Rankin AM; Faller DV; Spanjaard RA
Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
[TBL] [Abstract][Full Text] [Related]
2. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.
Herbert BS; Pongracz K; Shay JW; Gryaznov SM
Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790
[TBL] [Abstract][Full Text] [Related]
3. Oligonucleotide n3'-->p5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents.
Gryaznov SM
Chem Biodivers; 2010 Mar; 7(3):477-93. PubMed ID: 20232321
[TBL] [Abstract][Full Text] [Related]
4. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
5. Screening of telomerase inhibitors.
Kleideiter E; Piotrowska K; Klotz U
Methods Mol Biol; 2007; 405():167-80. PubMed ID: 18369824
[TBL] [Abstract][Full Text] [Related]
6. Oligonucleotide N3' --> P5' thio-phosphoramidate telomerase template antagonists as potential anticancer agents.
Gryaznov S; Asai A; Oshima Y; Yamamoto Y; Pongracz K; Pruzan R; Wunder E; Piatyszek M; Li S; Chin A; Harley C; Akinaga S; Yamashita Y
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):577-81. PubMed ID: 14565232
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
Tárkányi I; Aradi J
Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
[TBL] [Abstract][Full Text] [Related]
8. How to inhibit telomerase activity for cancer therapy.
Kyo S; Inoue M
Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):613-26. PubMed ID: 12678728
[TBL] [Abstract][Full Text] [Related]
9. Novel anticancer therapeutics targeting telomerase.
Ruden M; Puri N
Cancer Treat Rev; 2013 Aug; 39(5):444-56. PubMed ID: 22841437
[TBL] [Abstract][Full Text] [Related]
10. [Telomeres and telomerase as targeted therapies in cancer treatment].
Souiden Y; Bouraoui A; Chaieb K; Mahdouani K
Bull Cancer; 2010 Sep; 97(9):1087-104. PubMed ID: 20663741
[TBL] [Abstract][Full Text] [Related]
11. Telomere maintenance mechanisms as a target for drug development.
Bearss DJ; Hurley LH; Von Hoff DD
Oncogene; 2000 Dec; 19(56):6632-41. PubMed ID: 11426649
[TBL] [Abstract][Full Text] [Related]
12. Targeting human telomerase in cancer therapy.
Huard S; Autexier C
Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):577-87. PubMed ID: 12678725
[TBL] [Abstract][Full Text] [Related]
13. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
[TBL] [Abstract][Full Text] [Related]
14. Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition.
Herbert BS; Gellert GC; Hochreiter A; Pongracz K; Wright WE; Zielinska D; Chin AC; Harley CB; Shay JW; Gryaznov SM
Oncogene; 2005 Aug; 24(33):5262-8. PubMed ID: 15940257
[TBL] [Abstract][Full Text] [Related]
15. Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models.
Berardinelli F; Coluzzi E; Sgura A; Antoccia A
Mutat Res Rev Mutat Res; 2017 Jul; 773():204-219. PubMed ID: 28927529
[TBL] [Abstract][Full Text] [Related]
16. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
El Daly H; Martens UM
Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
[TBL] [Abstract][Full Text] [Related]
17. Telomerase: a potential therapeutic target for cancer.
Fletcher TM
Expert Opin Ther Targets; 2005 Jun; 9(3):457-69. PubMed ID: 15948667
[TBL] [Abstract][Full Text] [Related]
18. Anticancer therapy targeting telomeres and telomerase : current status.
Parkinson EK; Minty F
BioDrugs; 2007; 21(6):375-85. PubMed ID: 18020621
[TBL] [Abstract][Full Text] [Related]
19. Telomere targeting with a novel G-quadruplex-interactive ligand BRACO-19 induces T-loop disassembly and telomerase displacement in human glioblastoma cells.
Zhou G; Liu X; Li Y; Xu S; Ma C; Wu X; Cheng Y; Yu Z; Zhao G; Chen Y
Oncotarget; 2016 Mar; 7(12):14925-39. PubMed ID: 26908447
[TBL] [Abstract][Full Text] [Related]
20. Telomeres, telomerase and cancer: is the magic bullet real?
Sharma HW; Maltese JY; Zhu X; Kaiser HE; Narayanan R
Anticancer Res; 1996; 16(1):511-5. PubMed ID: 8615664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
